Recombinant human parathyroid hormone

Recombinant human parathyroid hormone
Clinical data
Trade names	Preotact, Natpara, Natpar
AHFS/Drugs.com	Monograph
MedlinePlus	a617013
License data	US DailyMed: Parathyroid hormone;
Routes of; administration	Subcutaneous
Drug class	Hormonal agent
ATC code	H05AA03 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
CAS Number	9002-64-6;
DrugBank	DB05829;
UNII	N19A0T0E5J;
KEGG	D05364;
Chemical and physical data
Formula	C408H674N126O126S2
Molar mass	9424.76 g·mol−1

Recombinant human parathyroid hormone, sold under the brand name Preotact among others, is an artificially manufactured form of the parathyroid hormone used to treat hypoparathyroidism (under-active parathyroid glands). Recombinant human parathyroid hormone is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures. A significant reduction in the incidence of vertebral fractures has been demonstrated. It is used in combination with calcium and vitamin D supplements.

The most common side effects include sensations of tingling, tickling, pricking, or burning of the skin (paraesthesia); low blood calcium; headache; high blood calcium; and nausea.

Recombinant human parathyroid hormone (Preotact) was approved for medical use in the European Union in April 2006. Recombinant human parathyroid hormone (Natpara) was approved for medical use in the United States in January 2015, and in the European Union (as Natpar) in February 2017.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.